Scientific Temper

Nutshells and last-month notes

Every topic of Biotechnology in two boxes: the nutshell that holds the idea, and the facts to carry into the exam hall.

The cell and its instruction manual: from one cell to an organism

In a nutshell

Every living thing is made of cells, and every cell carries an instruction manual written in DNA, in the same language for all life. Biotechnology is the art of reading and changing that manual, so it begins with the cell.

  1. A cell is like a city: the nucleus is the manager, DNA is its instruction manual, ribosomes are the factories and mitochondria supply the energy.
  2. Prokaryotes (bacteria, archaea) keep their DNA loose in the cell; eukaryotes (plants, animals, fungi, protists) protect it inside a nucleus. Mitochondria and chloroplasts were once free-living bacteria.
  3. You began as one cell. Division (mitosis) made more cells; differentiation made them different. Cells that can still become other types are stem cells.

One celldividesdifferentiatesabout 200 cell types, one organism

Last-month notes
  • Prokaryotes: bacteria and archaea; no nucleus; circular DNA, often with plasmids. Eukaryotes: protists, fungi, plants, animals; nucleus; linear chromosomes.
  • DNA locations: nucleus, mitochondria, and in plants chloroplasts. Mitochondrial DNA is inherited from the mother.
  • Mitochondria and chloroplasts came from bacteria by endosymbiosis; chloroplasts from a cyanobacterium.
  • Cell wall: present in bacteria, archaea, fungi and plants; absent in animal cells.
  • Viruses: DNA or RNA in a protein coat; not cells; multiply only inside a host cell. SARS-CoV-2 uses the ACE2 receptor; HIV uses CCR5.
  • Potency: totipotent (zygote, whole organism with placenta) → pluripotent (embryonic stem cells, not placenta) → multipotent (adult stem cells, e.g. bone marrow) → unipotent.
  • Blastocyst: outer layer → placenta; inner cell mass → embryo. Earth BioGenome Project (2018): all named eukaryotes, about 1.8 million species.

Statements to watch for

  • Embryonic stem cells are pluripotent, not totipotent.
  • Cell walls are not unique to plants.
  • A bigger genome does not mean a more complex organism.
  • Mature red blood cells have no nucleus and so no nuclear DNA.
  • Bacteria in the body are of the same order as human cells, not ten times more.

Stem cells and their uses: therapy, iPS cells, cloning and transplants

In a nutshell

Stem cell therapy uses stem cells, or cells grown from them, to replace cells the body has lost or cannot make properly. It is also changing how new drugs are tested.

  1. Find healthy stem cells: from the patient, from a donor whose tissue type (HLA) matches, or by reprogramming an ordinary adult cell into an iPS cell.
  2. Grow the cells that are needed: blood cells, corneal cells, nerve cells, heart muscle.
  3. Put them back, or test drugs on them: regenerative medicine on one side, faster and more personal drug development on the other.

Where things stand (Nov 2026): bone marrow (haematopoietic) stem cell transplants are established treatment; Japan approved the first iPS-cell products in March 2026; organs from gene-edited pigs are in clinical trials in the US.

Last-month notes
  • Stem cell therapy: two uses, regenerative medicine and drug testing. Cell therapy delivers cells; gene therapy delivers genes.
  • Haematopoietic stem cells (bone marrow) make all blood cells. Thalassaemia: too little haemoglobin. Sickle cell disease: abnormal, sickle-shaped red cells. Birsa 101: India's gene therapy for sickle cell disease.
  • HLA match decides transplant success; each sibling has about a 1 in 4 chance of a full match. Saviour sibling: IVF with embryo testing; India's first case, Ahmedabad (born 2018, transplant 2020).
  • ICMR–DBT guidelines (2017): only haematopoietic stem cell transplantation for approved blood disorders is established; all other stem cell use only in approved trials.
  • iPS cells: Yamanaka (2006); Nobel 2012 with Gurdon. Japan, March 2026: first approved iPS products (Parkinson's, Amchepry; heart sheets, ReHeart), conditional and time-limited.
  • SCNT: nucleus of a somatic cell into an enucleated egg. Gurdon's frogs (1960s); Dolly (1996, Roslin), first mammal from an adult cell. Clone's mitochondrial DNA comes from the egg donor.
  • Autologous (self) < allogeneic (same species) < xenogeneic (other species) in rejection risk. Pig kidney: record 271 days (Tim Andrews, 2025); US clinical trials cleared in 2025.

Statements to watch for

  • iPS cells are made from adult cells; no embryo is destroyed.
  • Parkinson's is the loss of dopamine-producing neurons in the brain, not a disease of motor neurons.
  • The cornea is the clear front surface of the eye, not the lens.
  • Siblings are often, not always, an HLA match.
  • Xenotransplants so far use gene-edited pig organs, not human organs grown in pigs.
  • An organoid is a model grown from stem cells, not a transplantable organ; bioprinted tissue is limited by the lack of a blood supply.

DNA as the code of life: the central dogma

In a nutshell

DNA is a cookbook written in four letters. The cell copies a recipe from it into a temporary photocopy, RNA, and the ribosome reads that copy to cook a protein. DNA → RNA → protein is the central dogma of biology, and all of biotechnology works on some part of it.

  1. Transcription (in the nucleus): a stretch of DNA is copied into messenger RNA.
  2. Translation (in the cytoplasm): the ribosome reads the RNA three letters at a time and joins amino acids into a protein.
  3. Shape is function: how the protein chain twists and folds decides what it does.

DNARNAProtein

Last-month notes
  • Double helix: Watson and Crick (1953), using Rosalind Franklin's X-ray images. Genetic code: Nirenberg, Har Gobind Khorana, Holley (Nobel 1968).
  • Base pairing: A–T, G–C, by hydrogen bonds. RNA uses U instead of T and ribose instead of deoxyribose; usually single-stranded and short-lived.
  • Transcription (nucleus): DNA → mRNA by RNA polymerase. Translation (ribosome): codon of 3 letters → 1 amino acid, brought by tRNA. 20 amino acids; 64 codons.
  • Humans: about 3.2 billion letters; 23 pairs of chromosomes (22 autosomes + XX or XY); only about 1.5–2% codes for protein.
  • PCR multiplies DNA by repeated heating and cooling with DNA polymerase. RT-PCR first turns RNA into DNA with reverse transcriptase.
  • Human Genome Project 1990–2003 (draft 2001); complete gap-free sequence 2022. Omics: genomics, transcriptomics, proteomics, metabolomics.
  • Nobel Chemistry 2024: Baker (protein design); Hassabis and Jumper (AlphaFold, structure prediction). India's bioeconomy: $195.3 bn (2025), up from $165.7 bn (2024); target $300 bn by 2030.

Statements to watch for

  • A gene is the coding part, not the whole genome or a whole chromosome.
  • Most of the genome does not code for protein, but it is not useless.
  • Viruses may have RNA as their genetic material; no cellular organism does.
  • PCR copies DNA; it cannot copy RNA without reverse transcription first.
  • The central dogma was proposed by Crick; Khorana helped crack the genetic code.

DNA as the vehicle of heredity: copying, variation and the mother's line

In a nutshell

DNA brings permanence: the same genome is copied into every cell from the zygote to death, and passed to children. It also brings variety: when sex cells form, each parent's two versions of every chromosome are shuffled, so every egg and every sperm is unique. Beside this runs a second, smaller line of inheritance, the DNA of the mitochondria, which comes only from the mother.

  1. Within a life: replication, proofreading, and telomeres that shorten with each division.
  2. Between generations: meiosis halves the chromosomes and recombines them; fertilisation restores the pair.
  3. The mother's line: mitochondrial DNA, used to trace ancestry and, when faulty, replaced by a donor's.

Parent's cells (two versions)Shuffled sex cell (one version)Zygote (two versions again)

Last-month notes
  • Replication with proofreading; uncorrected errors are mutations. Telomeres are protective caps at chromosome ends that shorten with each division; telomerase rebuilds them in stem cells and most cancer cells.
  • Alleles: two versions of a gene. Body cells diploid (46); sex cells haploid (23). Meiosis makes sex cells; crossing over (recombination) makes each one unique.
  • Identical twins: one zygote, same nuclear DNA. Fraternal twins: two eggs, two sperm. Unrelated people share about 99.9% of DNA letters.
  • Sickle cell allele: harmful in two copies, protective against malaria in one; hence common in malaria regions.
  • Plant cells can de-differentiate. Tissue culture: explant → callus → plant. Micropropagation: many identical, disease-free plants (banana, sugarcane, potato, orchids). Somaclonal variation: genetic change in culture.
  • Mitochondrial DNA: about 16,500 letters, 37 genes, maternal only, no recombination. Mitochondrial Eve: about 150,000–200,000 years ago, inferred from living people's DNA.
  • Most mitochondrial proteins are encoded by nuclear genes; only 37 genes sit in mitochondrial DNA. Mitochondrial disease can therefore be maternally or ordinarily inherited.
  • MRT: spindle transfer (before fertilisation), pronuclear transfer (after). UK legal 2015; first birth 2016 (Mexico, spindle transfer); UK 2025 report: eight babies (pronuclear transfer).
  • Svante Pääbo, Nobel Medicine 2022: Neanderthal genome, Denisovans; interbreeding with modern humans.

Statements to watch for

  • Variety is introduced when sex cells form (meiosis), not at fertilisation.
  • Mitochondrial DNA is inherited only from the mother, but a mitochondrial disease caused by a nuclear gene can come from either parent — and MRT does not help in that case.
  • MRT does not make the donor a parent in the ordinary sense: she contributes only mitochondrial DNA.
  • MRT can be done before or after fertilisation.
  • Mitochondrial Eve was not the first or only woman of her time.
  • Duchenne muscular dystrophy is caused by a gene in the nucleus (on the X chromosome), not by mitochondrial DNA.

Reading the genome: genes, their switches and the non-coding 98 per cent

In a nutshell

Reading the whole human genome showed that genes are only about 1.5 to 2 per cent of it, and that about 20,000 genes produce many times that number of proteins. What matters is not only which genes you have but which are switched on, when, and how much: gene expression. Much of the "junk" turns out to be switches and regulators, and medicine is learning to act on them.

  1. Before transcription: switches on the DNA decide which recipes a cell reads.
  2. After transcription: the RNA copy is cut and joined (splicing), so one gene can give several proteins.
  3. Before translation: small RNAs can silence or dim the message.

Same genome in every cellDifferent genes expressedDifferent cells

Last-month notes
  • Human genome: about 20,000 protein-coding genes, about 1.5–2% of the DNA; far more proteins than genes.
  • Gene expression controls: promoters, transcription factors, histones (tight = silent), DNA methylation (generally silences). Epigenetics: changes in gene activity without changing the DNA letters.
  • Exons code and are kept; introns are cut out. Splicing makes mature mRNA; alternative splicing gives several proteins from one gene.
  • Rough ER has ribosomes and makes proteins; smooth ER has none.
  • Non-coding RNA: tRNA, rRNA, lncRNA (>200 letters), siRNA (silences mRNA: RNA interference), miRNA (dims mRNA). Nobel: RNAi 2006 (Fire, Mello); miRNA 2024 (Ambros, Ruvkun).
  • RNAi uses: gene-silencing therapies, cancer research, virus- and pest-resistant crops, RNAi sprays. Not for replacing a missing protein. First siRNA drug: patisiran (US, 2018).
  • Small molecules → generics; biologics (insulin, antibodies, vaccines) → biosimilars.
  • Transposons (jumping genes; McClintock; nearly half the genome). Endogenous retroviruses: about 8%.
  • Sequencing: Sanger (one piece at a time) → next-generation (short reads, massively parallel) → long-read (nanopore). Hachimoji DNA: eight letters (2019).

Statements to watch for

  • One gene does not mean one protein.
  • Exons are the coding parts; introns are removed.
  • Epigenetic changes alter gene activity, not the DNA sequence.
  • RNA interference acts on mRNA, not on DNA; it does not change the genome.
  • A biosimilar is a near-copy of a biologic, not a chemical imitation of one.
  • Methylation of DNA generally switches genes off.

Identity markers in the genome: fingerprints, barcodes, SNPs and DNA from the environment

In a nutshell

Some patterns in the genome work like identity cards. Repeated words that vary in number tell one person from another (DNA fingerprinting). A standard stretch of mitochondrial DNA tells one species from another (DNA barcoding). Single-letter differences, inherited down the generations, tell populations apart and trace ancestry (SNPs). Each tool reads a different pattern, so each answers a different question, and none of them reads what a gene does.

  1. Which individual? Microsatellites (short tandem repeats): fingerprinting.
  2. Which species? The COI region of mitochondrial DNA: barcoding.
  3. Which population, which ancestors, which risks? SNPs, Genome India, association studies.

Pattern in the DNAWhat it can identifyWhat it cannot

Last-month notes
  • DNA fingerprinting: Alec Jeffreys (1984); in India, Lalji Singh (CCMB); CDFD, Hyderabad. Microsatellites/STRs (2–6 letter units) used today; minisatellites/VNTRs (10–100).
  • DNA Technology Bill 2019 withdrawn July 2023; Criminal Procedure (Identification) Act 2022 allows collection of biological samples. US database: CODIS. Privacy: Puttaswamy (2017).
  • DNA barcoding: COI (mitochondrial) for animals; chloroplast genes for plants. Species identification, trafficking, food fraud.
  • eDNA: DNA shed into water, soil, air. Metagenome: all genetic material in a sample. Aerial metagenomics: DNA from air to know species in a habitat.
  • SNPs: single-letter variations; ancestry, population genomics, GWAS, pharmacogenomics. Rakhigarhi ancient DNA (2019). Non-Africans: about 1–2% Neanderthal DNA.
  • Genome India: DBT, launched 2020; about 10,000 genomes; data at IBDC Faridabad (Jan 2025); about 180 million variants (April 2025).
  • Pan-genome: reference from many individuals; human pangenome draft (2023, 47 people); crop pan-genomes for wild-variety genes.
  • Gene chip / DNA chip: tests known gene variants (e.g. BRCA1, BRCA2) or gene activity.

Statements to watch for

  • DNA fingerprinting cannot distinguish identical twins.
  • DNA barcoding identifies species, not individuals, and cannot tell an organism's age.
  • Microsatellite markers are used in evolutionary and population studies, not only in forensics.
  • A GWAS finds associations, not proof of cause.
  • Identity markers come mainly from non-coding DNA; gene chips read the coding part.
  • Genome India sequenced about 10,000 people; it is not a pan-genome of all Indians.
  • A probiotic is defined by intended benefit and by strain; evidence for one strain in one condition does not establish benefit for every product.

From recombinant DNA to gene editing: cutting and pasting the code of life

In a nutshell

Manipulating the code of life has moved from cutting in the dark to writing with a pen. Recombinant DNA technology, from the 1970s, cuts a gene from one organism and pastes it into another, producing a transgenic organism; but it cannot choose exactly where to cut or paste. Gene editing, above all CRISPR-Cas9, reads the DNA sequence and cuts at the chosen spot, so it can delete or change a few letters without bringing in foreign DNA. India regulates the two differently.

  1. Recombinant DNA: scissors, glue and a carrier, copied from bacteria and viruses.
  2. Gene editing: a guide that finds the exact spot, and scissors that cut there.
  3. Beyond: base and prime editing, gene drives, synthetic biology.

Copy and paste whole genesEdit chosen lettersWrite new code

Last-month notes
  • rDNA tools: restriction enzymes (bacterial defence against phages; cut at specific short sequences), DNA ligase (joins), vectors (plasmids, phages, viruses, yeast/bacterial artificial chromosomes; Agrobacterium for plants). First rDNA organism: Cohen and Boyer, 1973.
  • Plasmids spread antibiotic resistance by horizontal gene transfer.
  • Gene library; cDNA library (from mRNA by reverse transcriptase; no introns).
  • Golden Rice: beta-carotene genes from daffodil and a bacterium (later maize); Philippines approval 2021, halted by court 2024.
  • rDNA products: human insulin (1978; approved 1982), growth hormone, clotting factors, hepatitis B vaccine (India: Shanvac-B, 1997).
  • CRISPR = clustered regularly interspaced short palindromic repeats; guide RNA (torch) + Cas9 (scissors). Doudna and Charpentier, Nobel Chemistry 2020.
  • SDN-1 (delete), SDN-2 (small planned change), SDN-3 (insert gene, transgenic). India exempted SDN-1/2 without foreign DNA, March 2022.
  • Cas12 (DNA), Cas13 (RNA); FELUDA (CSIR-IGIB). Base editing (one letter, no double cut), prime editing (search and replace). TnpB: ICAR-CRRI, patent Sept 2025.
  • Gene drive: near-100% inheritance; no open release approved. Synthetic biology: synthetic genome cell, 2010.
  • Patents Act s. 3(j): no patents on plants, animals, seeds; microorganisms patentable.
  • Mosquito interventions: gene drive (edit copies itself, spreads); self-limiting engineered males (offspring do not survive); Wolbachia (bacterium, maternally transmitted, blocks dengue transmission; ICMR-VCRC Puducherry with the World Mosquito Program).

Statements to watch for

  • Restriction enzymes come from bacteria, not viruses.
  • A genome-edited crop is not necessarily transgenic; a GM crop made by rDNA always is.
  • India's exemption covers SDN-1 and SDN-2 only, and only without foreign DNA.
  • Cas13 targets RNA, not DNA.
  • Golden Rice makes beta-carotene (provitamin A), not vitamin A itself.
  • In CRISPR-Cas9, the RNA guides and the protein cuts.
  • Wolbachia mosquitoes are not genetically engineered: the bacterium is introduced and then passes from mother to offspring. A gene drive spreads an edit; self-limiting releases leave nothing behind.

GM and genome-edited crops: Bt cotton, GM mustard, edited rice and the rules

In a nutshell

Crops are engineered to resist pests or herbicides, survive drought or salt, yield more, carry more nutrients, keep longer, or even make medicines. In India, Bt cotton remains the only GM crop grown commercially; GM mustard was cleared by the regulator in 2022 but is held up in the Supreme Court; and two genome-edited rice varieties were released in 2025 under the lighter rules for edits that add no foreign DNA. Behind each case lie questions of safety, ecology, farmers' costs and who owns seeds.

  1. The technology: transgenic (GM) or edited without foreign DNA.
  2. The cases: Bt cotton, HTBt cotton, GM mustard, genome-edited rice.
  3. The rules: GEAC and the 1989 Rules; the Cartagena Protocol; patents and farmers' rights.

Trait wantedTechnique chosenRegulatory route

Last-month notes
  • Bt: Bacillus thuringiensis Cry proteins rupture the gut of specific insects. Bt cotton 2002 (Bollgard), Bollgard II 2006; over 90% of cotton area.
  • Pink bollworm resistance: Bollgard by ~2008–09, Bollgard II by mid-2010s; refuges not planted. Whitefly in Punjab, 2015.
  • Glyphosate: IARC "probably carcinogenic" (2015); India restricted use to pest control operators (October 2022). HTBt cotton not approved.
  • GM mustard DMH-11 (Delhi University, CGMCP): Varuna (barnase, male-sterile) × Early Heera-2 (barstar, restorer); bar gene: glufosinate tolerance. GEAC approval Oct 2022; SC split verdict July 2024.
  • Genome-edited rice (May 2025): DRR Dhan 100 Kamala (IIRR; from Samba Mahsuri) and Pusa DST Rice 1 (IARI; from MTU 1010).
  • Swarna-Sub1 (scuba rice): flood-tolerant, conventional marker-assisted breeding, not GM.
  • Rules 1989 under EP Act 1986; committees RDAC, IBSC, RCGM (DBT), GEAC (MoEFCC), SBCC, DLC. Cartagena Protocol (2000; in force 2003).
  • PPVFR Act 2001: farmers may save, sow, share and sell seed but not as branded seed. GURT ("terminator"): CBD moratorium 2000; never commercialised.
  • Access and benefit sharing: Nagoya Protocol (2010, in force 2014) under the CBD; India's Biological Diversity Act 2002, with the NBA, State Biodiversity Boards and Biodiversity Management Committees (People's Biodiversity Registers).
  • Biopiracy cases: turmeric and neem patents revoked, basmati claims narrowed; Traditional Knowledge Digital Library created as searchable prior art. Digital sequence information is the live dispute.
  • First GM food: Flavr Savr tomato (1994). Plant-made medicine: enzyme from carrot cells (2012).

Statements to watch for

  • Bt cotton is the only GM crop commercially cultivated in India; genome-edited rice is not legally a GM crop.
  • Barnase causes male sterility; barstar restores fertility.
  • The Bt protein is specific to certain insects; it is not a broad-spectrum poison.
  • GEAC is under the environment ministry, not the agriculture ministry.
  • The terminator moratorium came under the Convention on Biological Diversity; the Cartagena Protocol governs the movement of living modified organisms across borders.
  • Edible vaccines are still experimental.
  • The Nagoya Protocol governs access to genetic resources and the sharing of benefits; the Cartagena Protocol governs transboundary movement of living modified organisms. Both sit under the Convention on Biological Diversity.
  • The turmeric and neem patents were revoked and the basmati claims narrowed; the TKDL exists to make such knowledge searchable as prior art.

Gene therapy: correcting the code in patients

In a nutshell

Gene therapy treats disease by delivering genetic material into a patient's cells: to edit a faulty gene, to add a working copy, or to regulate how a gene is read. It works best where one known gene causes the disease, which is why blood disorders such as sickle cell disease, thalassaemia and haemophilia, and blood cancers treated with engineered immune cells, came first. The challenges are getting the gene into the right cells safely, and the cost.

  1. What is changed: the DNA (permanent) or the RNA (temporary).
  2. Where: inside the body (in vivo) or in cells taken out and returned (ex vivo).
  3. How it is carried: viral vectors (lentivirus, AAV) or non-viral carriers (lipid nanoparticles).

Faulty geneEdit, add or regulateWorking protein

Last-month notes
  • Gene therapy: editing (permanent), addition, RNA-based regulation (temporary). Works best for monogenic diseases; blood disorders first.
  • First gene therapy trial: 1990 (US), for a form of SCID. National Policy for Rare Diseases, 2021.
  • Casgevy: CRISPR disables BCL11A switch → foetal haemoglobin; ex vivo; approved UK Nov 2023, US Dec 2023; first CRISPR medicine.
  • BIRSA 101: CSIR-IGIB, enFnCas9, launched Nov 2025, technology to Serum Institute. National Sickle Cell Anaemia Elimination Mission (2023, target 2047).
  • CMC Vellore: haemophilia A, lentiviral factor VIII gene addition, five patients, zero bleeds (results Dec 2024).
  • CAR-T: chimeric antigen receptor on patient's T cells; NexCAR19 (ImmunoACT/IIT Bombay, Tata Memorial), approved Oct 2023. Nobel Medicine 2025: regulatory T cells.
  • Vectors: lentivirus/retrovirus integrate (dividing cells); AAV mostly does not (non-dividing cells: retina, muscle, liver); lipid nanoparticles (mRNA).
  • Somatic vs germline; He Jiankui (2018, CCR5). ICMR gene therapy guidelines 2019: germline prohibited.

Statements to watch for

  • Casgevy is the first approved CRISPR therapy, not the first gene therapy.
  • Gene therapy can add a whole working gene with a viral vector; it is not limited to editing.
  • CAR-T cell therapy is done ex vivo.
  • Somatic gene therapy is not inherited; germline changes would be.
  • Haemophilia genes are on the X chromosome, which is why it mostly affects males.
  • siRNA is given as a medicine; microRNA is mainly a biomarker and a drug target.

Medicines from biotechnology: proteins, antibodies, vaccines and cancer

In a nutshell

Most of biotechnology's effect on health is not gene therapy at all. It is the manufacture of proteins that the body needs or that fight disease: insulin, clotting factors, antibodies and vaccines. All of these work on the immune system or on the body's own chemistry, and they are made by engineered cells rather than by chemical synthesis.

  1. Proteins as medicines: made by engineered microbes or cells (recombinant DNA).
  2. Vaccines: show the immune system a pathogen's marker before the real infection.
  3. Hard problems: cancer, which is our own cells, and microbes that outrun our drugs.

Known protein or antigenEngineered cells make itMedicine or vaccine

Last-month notes
  • Recombinant insulin: first rDNA medicine (1982). Type 1: beta cells destroyed, no insulin. Type 2: insulin resistance.
  • Immunity: innate (general) and adaptive (specific, remembered); B cells make antibodies, T cells kill. Antigen = marker; antibody = protein that binds it.
  • Monoclonal antibodies: identical copies of one antibody; Köhler and Milstein, Nobel 1984; names end in -mab. Checkpoint inhibitors: Nobel 2018.
  • Vaccine types: live attenuated (BCG, measles, OPV), inactivated (IPV, Covaxin), subunit/recombinant (hepatitis B, HPV), viral vector (Covishield), mRNA (GEMCOVAC-OM, 2023), DNA (ZyCoV-D, 2021, world's first human DNA vaccine).
  • Cervavac: India's first indigenous quadrivalent HPV vaccine (Serum Institute with DBT), 2022.
  • Malaria: Plasmodium changes surface antigens at each life stage, so natural infection gives no lasting immunity. RTS,S recommended by WHO 2021; R21/Matrix-M (Oxford and Serum Institute) October 2023.
  • Cancer: oncogenes (accelerator) and tumour suppressor genes (brake); benign vs malignant; metastasis. Chemotherapy and radiotherapy are not selective; targeted therapy, checkpoint inhibitors, CAR-T and therapeutic cancer vaccines are.
  • AMR: mutation plus plasmid-borne horizontal gene transfer; superbugs; NDM-1 (first reported 2008) destroys carbapenems; Candida auris; WHO fungal priority list 2022; National Action Plan on AMR; One Health.
  • Phage therapy: bacteriophages co-evolve with bacteria; narrow host range; used on compassionate grounds.

Statements to watch for

  • mRNA vaccines do not alter the recipient's DNA and do not enter the nucleus.
  • A vaccine supplies the antigen; the body makes the antibodies.
  • Monoclonal means one antibody against one antigen, not one dose or one patient.
  • RTS,S and R21 reduce malaria substantially but do not give complete protection.
  • Phage therapy targets bacteria, not viruses, and is not yet a general substitute for antibiotics.
  • HPV and hepatitis B vaccines prevent cancers by preventing infections; therapeutic cancer vaccines treat existing cancer.
  • A biofilm's drug tolerance comes from the community and its protective layer, not only from resistance genes.
  • A liquid biopsy samples tumour material circulating in blood; a negative result does not rule out cancer.

Biotechnology in the environment and industry: cleaning, growing and making

In a nutshell

Most biotechnology in daily use is not editing genomes at all. It is putting ordinary organisms to work: bacteria that eat spilled oil, microbial communities that clean sewage, fungi and bacteria that make soil nutrients available to roots, and yeasts and moulds that manufacture fuel, enzymes and medicines in tanks. The science is older than genetic engineering and the scale is far larger, but the organisms work only within the conditions they tolerate.

  1. Degrade: break down what we want removed, as in bioremediation and sewage treatment.
  2. Supply: make nutrients available in soil, as biofertilisers and mycorrhiza do.
  3. Produce: manufacture fuels, enzymes, acids and proteins by fermentation.

ProblemOrganism with the right appetiteConditions it needsOutcome and its limit

Last-month notes
  • Bioremediation: biostimulation (add nutrients/oxygen to native microbes) vs bioaugmentation (add selected organisms); in-situ vs ex-situ; phytoremediation uses plants.
  • Oilzapper: TERI, with DBT support; work from 1993, consortium around 2000; carrier-based mix of naturally occurring oil-degrading bacteria; used by ONGC, IOCL, BPCL, Oil India; ONGC-TERI Biotech Ltd. Not genetically engineered.
  • BOD: oxygen microbes would need to break down the organic matter in water; a measure of organic pollution load.
  • Biofilter: microbes as a biofilm on a fixed medium, converting pollutants; also used for odour control. Membrane bioreactor: biological treatment plus membrane separation in one unit, small footprint, water fit for reuse, higher energy and fouling.
  • Nitrogen fixers: Rhizobium (root nodules of legumes, symbiotic); Azotobacter, Azospirillum (free-living); cyanobacteria (blue-green algae) and Azolla (fern with a cyanobacterium) in rice fields.
  • Phosphate-solubilising bacteria release bound phosphorus. Mycorrhiza: fungus-root association extending the absorbing surface for phosphorus and water; used in mine-spoil and wasteland rehabilitation.
  • Biopesticides: Bt sprays, Trichoderma, baculoviruses (NPV), neem azadirachtin. Narrow-spectrum, short-lived.
  • Ethanol: 1G from sugarcane juice, molasses or grain; 2G from crop residue, needing cellulose breakdown first. Government statement July 2026: average 20% blending (E20) reached in supply year 2025–26, five years ahead of the original target.
  • Biogas: anaerobic digestion to methane and carbon dioxide; purified as compressed biogas. SATAT target 5,000 CBG plants; GOBARdhan for incentives.
  • Bioplastics: PLA from fermented plant sugar; PHA stored inside bacteria.
  • Alternative proteins: plant-based, fermentation-derived (including precision fermentation), cultivated cells. In India these are novel foods; no cultivated meat approved for sale.

Statements to watch for

  • Bioremediation can degrade organic pollutants but cannot degrade heavy metals, which can only be immobilised, moved or concentrated.
  • A biofilter converts pollutants biologically; it does not work by straining them out. A membrane does the separating.
  • A membrane bioreactor combines biological treatment and membrane separation in the same unit, which is why no separate settling tank is needed.
  • Biofertilisers do not supply nutrients directly; they fix nitrogen or make bound nutrients available.
  • Rhizobium fixes nitrogen only in symbiosis with a legume; Azotobacter and Azospirillum fix it living free.
  • Phosphate-solubilising bacteria add no phosphorus to the soil.
  • Azolla is a fern; the nitrogen fixing is done by the cyanobacterium it harbours.
  • A Bt spray is a biopesticide; a Bt crop carries the gene. They are not the same intervention.
  • A bioplastic is not necessarily biodegradable, and a biodegradable plastic may need industrial composting conditions.
  • Cultivated meat is grown from animal cells; plant-based and fermentation-derived proteins involve no animal cell culture.
Biotechnology: revision · Scientific Temper